Skip to main content
S&P 5007,684.55+0.10%DOW52,267.50-0.18%NASDAQ26,253.27+0.32%BTC$79,829.00+0.41%ETH$2,314.99+0.83%GOLD$4,040.20+0.04%OIL$101.45-0.30%
Smart Investors Daily
SID Premium
FA

NASDAQ · FATE

Fate Therapeutics, Inc.

Healthcare · Biotechnology

$2.06

Down-$0.01 (-0.49%)

Updated Oct 27, 2026, 2:06 PM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
128M
P/E ratio
-0.85
Dividend yield
0.00%
52-week range
$0.95 – $3.23
Volume
1.46M
Avg. volume
2.11M

Price performance · FATE

FATE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

FATE closed at $2.06 after 21 trading sessions, down 13.66% for the selected period.

Last close
$2.06
Period change
-13.66%
Period low
$1.79
Period high
$2.43
Daily close
View OHLC price history
FATE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$2.10$2.14$2.04$2.0551.46M
Oct 23, 2026$2.08$2.135$2.015$2.111.11M
Oct 22, 2026$2.07$2.11$2.035$2.09867.18K
Oct 21, 2026$2.06$2.14$2.045$2.071.22M
Oct 20, 2026$1.86$2.145$1.84$2.061.77M
Oct 19, 2026$1.79$1.90$1.75$1.861.68M
Oct 16, 2026$1.94$1.975$1.78$1.791.38M
Oct 15, 2026$1.96$1.995$1.91$1.9251.16M
Oct 14, 2026$1.95$1.99$1.89$1.941.67M
Oct 13, 2026$2.13$2.13$1.98$2.00953.48K
Oct 12, 2026$2.13$2.18$2.104$2.13616.85K
Oct 9, 2026$2.13$2.275$2.10$2.18773.47K
Oct 8, 2026$2.12$2.13$2.03$2.131.48M
Oct 7, 2026$2.28$2.30$2.14$2.15863.01K
Oct 6, 2026$2.43$2.49$2.285$2.291.14M
Oct 5, 2026$2.32$2.575$2.29$2.433.38M
Oct 2, 2026$2.34$2.36$2.27$2.32658.02K
Oct 1, 2026$2.37$2.39$2.285$2.30812.98K
Sep 30, 2026$2.40$2.495$2.355$2.371.08M
Sep 29, 2026$2.37$2.41$2.29$2.381.44M
Sep 28, 2026$2.30$2.42$2.27$2.381.16M

Latest FATE news

The latest Smart Investors Daily articles mentioning FATE.

Stock researchCompany · Overview

FATE research

Overview

Company profile and research snapshot.

Company profile

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$39.50
Implied upside
—
Analysts
—
FATE recent ratings
DateFirmRatingTarget
Aug 14, 2026Wells FargoEqual-Weight—
Aug 14, 2026Piper SandlerOverweight—
Aug 14, 2026WedbushOutperform—
Jun 8, 2026HC Wainwright & Co.Buy—
May 4, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 62,900 shares of the Company’s common stock

Yahoo · Oct 1, 2026

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026. 2026 Jefferies Global Healthcare Conference Location: London, UK Date: November 16th

Yahoo · Sep 25, 2026

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to fund advancing clinical trials for stem cell and gene therapies that have the potential to provide transformative benefits to patients and the healthcare system SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical c

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By